Introduction
============

Circadian rhythms are ubiquitous biological oscillations with an approximate 24-h period. These evolutionarily well-conserved rhythms arise from an intrinsic timekeeping system known as the "circadian clock", which allows organisms to anticipate environmental cycling and coordinate biological processes. This clock is self-sustainable through an elaborate cooperation of genetic components and is hierarchically organized into a circadian timing system. In mammals, the apex of this system is the suprachiasmatic nucleus (SCN) of the hypothalamus, which is considered the central or master clock ([@B65]; [@B67]). The SCN integrates environmental cues such as light into time information to entrain its phase and then conveys this information to other oscillators in extra-SCN brain regions and peripheral tissues. Indeed, in multi-cellular organisms, most cells harbor cell-autonomous oscillators. These so-called local or peripheral clocks contribute to overt circadian rhythms, including the rest-activity cycle, periodic daily variations in metabolism and body temperature, as well as rhythmic hormone secretion ([@B15]; [@B78]).

Robust circadian timing is required for health, and disruption of these intrinsic rhythms causes diverse pathologies. For instance, circadian disruption caused by shift-work, jet-lag, or mis-timed food intake is considered a risk factor for various chronic diseases, including sleep disorders, metabolic syndromes, cardiovascular diseases, affective disorders, neurodegeneration, and tumorigenesis ([@B82]; [@B5]). To develop treatments for these disorders, extensive studies have identified several small molecule compounds that can directly modulate circadian clocks. In this mini-review, we will discuss recent investigations of the most promising of these small chemical compounds and their therapeutic implications in neuropsychiatric diseases.

The Mammalian Circadian Molecular Clock
=======================================

The self-sustainable nature of the circadian system is primarily attributed to circadian molecular oscillators. The molecular clock is composed of several clock proteins that are required for the generation and maintenance of cell-autonomous rhythms ([@B15]). Clock proteins form two interlocking positive and negative transcription/translation feedback loops that drive periodic expression of their target genes (Figure [1](#F1){ref-type="fig"}). The primary regulators are Circadian Locomotor Output Cycle Kaput (CLOCK) and Brain Muscle Aryl Hydrocarbon Receptor Nuclear Translocator-Like 1 (BMAL1, encoded by the *ARNTL* gene). They belong to the basic helix-loop-helix--PER-ARNT-SIM (bHLH--PAS) transcription factor family. CLOCK and BMAL1 activate transcription of target genes by forming heterodimers and binding to E-box enhancer elements (5′-CACGTG-3′) in the promoter/enhancer regions. In addition to CLOCK, Neuronal PAS 2 (NPAS2) is another bHLH--PAS protein enriched in forebrain regions that can also form heterodimers with BMAL1 to control E-box element-dependent gene transcription ([@B2]). The targets include proteins that form a negative feedback loop such as PERIODs (PERs: PER1, 2, and 3) and CRYPTOCHROMEs (CRYs: CRY1 and 2). Accumulated PER and CRY proteins form repressive complexes that suppress E-box-mediated transcription by binding to CLOCK/BMAL1 heterodimers, whereas PER and CRY degradation terminates this repression and reinitiates transcription ([@B18]; [@B30]; [@B44]; [@B73]). Stability of PER and CRY proteins is linked with their post-translational modifications and is crucial for proper circadian period length. It is well known that the *Tau*-mutant hamster, bearing a mutation in the casein kinase 1𝜀 (*CK1𝜀*) gene, displays a shortened free-running period in locomotor activities ([@B66]). In accordance, PER proteins are phosphorylated by CK1s prior to their proteasomal degradation, contributing to regulation of circadian period lengths ([@B16]; [@B74]). Similarly, CRY protein phosphorylation by adenosine monophosphate-activated protein kinase (AMPK) or glycogen synthase kinase 3β (GSK3β) leads to degradation mediated by paralogous F-box proteins, FBXL3 and FBXL21 ([@B7]; [@B46]; [@B45]; [@B27]; [@B100]). Mutations in the *Fbxl3* gene result in long-period phenotypes in mice, whereas *Fbxl21*-mutant mice display short-period phenotypes ([@B19]; [@B75]; [@B27]; [@B100]). This CLOCK/BMAL1-initiated loop is considered the core loop of the mammalian clock.

![The mammalian circadian molecular clock and its potential drug targets. The mammalian circadian clock is composed of two interlocking transcription/translation feedback loops, the core and stabilizing/auxiliary loops, respectively. The integral components of the core loop are CLOCK (or NPAS2) and BMAL1, which form a heterodimer and then induce E-box-mediated transcription of their negative regulators *Period*s (PERs) and *Cryptochrome*s (CRYs). Accumulated PER and CRY proteins repress E-box-mediated transcription until they are sufficiently cleared by proteasome-mediated degradation. CLOCK and BMAL1 also control expression of circadian nuclear receptors such as RORs and REV-ERBs, which modulate *Bmal1* mRNA levels by competitive actions on the RORs/REV-ERBs-responsive elements (RREs) in the *Bmal1* promoter. Collectively, cycling of clock components determines the periodic mRNA expression levels of various clock-controlled genes (CCGs) through E-box, RRE, and/or other *cis*-elements recognized by secondary circadian transcription factors, thus generating rhythmic physiological outputs. Of these core clock proteins, we focused primarily on CRYs, REV-ERBs, and RORs (red boxes), which were recently identified as targets for small molecule modifiers of the circadian clock.](fnmol-11-00496-g001){#F1}

An additional stabilizing loop adjusts the amounts of bHLH--PAS proteins. This secondary loop consists of sets of the circadian nuclear receptors, in particular REV-ERBs (REV-ERBα and β, encoded by *NR1D1* and *NR1D2*, respectively) and retinoic acid receptor-related orphan nuclear receptors (RORs: RORα-γ), that are also under the transcriptional control of CLOCK/BMAL1 heterodimers. REV-ERBs and RORs compete to occupy the RORs/REV-ERBs-responsive elements (RREs) located in the promoter/enhancer regions of their target genes. RORs usually activate RRE-mediated transcription, whereas REV-ERBs strongly suppress it ([@B63]; [@B84]; [@B69]). This stabilizing loop was originally considered as accessory because only moderate phenotypes were observed in mutant mice bearing null alleles of any of these genes. However, more recent studies using inducible double knockouts for both *Nr1d1* and *2* revealed that their compensatory activity yielded these subtle phenotypes and that REV-ERBs are required for normal period regulation ([@B10]). REV-ERBs also control circadian outputs by cooperating with cell type-specific transcriptional regulators ([@B13]; [@B102]). Additional feedback loops involving the proline and acidic amino acid-rich basic leucine zipper proteins (PARbZip), such as D-box binding protein (DBP) and E4 promoter-binding protein 4 (E4BP4), as well as several members of bHLH transcription factors (BHLHE40 and BHLHE41), also intersect with the main loops to confer further regulation and mediate circadian expression of subsets of clock-controlled genes ([@B55]; [@B31]).

Small Molecules Targeting Clock Proteins
========================================

As noted earlier, circadian disruptions are pivotal in various biological dysfunctions. Subsequent studies have attempted to correct these dysfunctions by exploring pharmacological strategies ([@B71]). Initially, high-throughput screening studies identified several compounds that influence circadian oscillators by acting on post-translational regulators, including CK1s, CK2, GSK3β, and AMPK ([@B9]). These studies have advanced our understanding of the post-translational mechanisms underlying the circadian clock and uncovered novel clock-regulatory pathways. Additionally, some of the clock modulators that target these signaling pathways have already been recognized for their therapeutic implications ([@B25]; [@B9]). For example, lithium, a widely used mood stabilizer, inhibits GSK3β and lengthens the circadian period; however, some synthetic inhibitors exhibited opposite effects ([@B29]; [@B49]). Also, AMPK activators with a wide range of beneficial metabolic and physiological effects also altered circadian gene expression, as demonstrated both *in vivo* and *in vitro* ([@B85]; [@B46]). These observations suggest that modulation of the circadian clock may have beneficial effects on circadian rhythm-related chronic diseases. In this regard, recent investigations have attempted to directly target core components of the mammalian circadian clock by using small-molecule modifiers. Representative small molecules that bind to core clock components are summarized in Table [1](#T1){ref-type="table"}. Pharmacological targets of these small molecules include CRYs, REV-ERBs, and RORs, which are described below.

###### 

Representative small molecule clock modulators.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Name                           Structure                      Actions                                                                  Potential applications                                               Reference
  ------------------------------ ------------------------------ ------------------------------------------------------------------------ -------------------------------------------------------------------- ----------------------------------------
  KL001 and analogs              ![](fnmol-11-00496-i001.jpg)   CRY stabilizer\                                                          Metabolic disorders                                                  [@B28]; [@B59]
                                                                Suppresses E-box-mediated transcription\                                                                                                      
                                                                Alters period                                                                                                                                 

  KS15                           ![](fnmol-11-00496-i002.jpg)   CRY inhibitor Enhances E-box-mediated transcription                      Cancer                                                               [@B12], [@B11];\
                                                                                                                                                                                                              [@B34]

  SR9009 and related compounds   ![](fnmol-11-00496-i003.jpg)   REV-ERB agonist Suppresses RRE-mediated transcription                    **Sleep disorders Anxiety disorders** Metabolic disorders Cancer     [@B77]; [@B3]; [@B81]

  SR8278                         ![](fnmol-11-00496-i004.jpg)   REV-ERB antagonist Enhances RRE-mediated transcription                   **Depressive disorders Risk of bipolarity**                          [@B38]; [@B13]; [@B23]

  Nobiletin                      ![](fnmol-11-00496-i005.jpg)   RORα/γ agonist Enhances RRE-mediated transcription Increases amplitude   **Depressive disorders Neurodegeneration** Metabolic disorders       [@B61]; [@B98]; [@B97]; [@B58]; [@B26]

  SR1078 and related compounds   ![](fnmol-11-00496-i006.jpg)   RORα/γ agonist Enhances RRE-mediated transcription                       **Autism-spectrum disorders** Diabetic cardiomyopathy                [@B91], [@B90]; [@B103]

  SR1001 and related compounds   ![](fnmol-11-00496-i007.jpg)   RORα/γ inverse agonist Suppresses RRE-mediated transcription             Metabolic disorders Atherosclerosis Autoimmunity Anti-inflammation   [@B76]; [@B6]; [@B14]

                                                                                                                                                                                                              
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CRY, cryptochrome; ROR, retinoic acid receptor-related orphan nuclear receptor; RRE, RORs/REV-ERBs-responsive element.

CRYs: Key Targets of Small Molecules That Act Directly on the Core Loop
-----------------------------------------------------------------------

A carbazole derivative, KL001, and its analogs are the first-in-class small molecules that target the core components of the mammalian clock ([@B28]). In cultured SCN explants and fibroblasts, continuous treatment with these compounds significantly lengthens the circadian period and reduces amplitude of both *Bmal1* and *Per2* promoter activity, implying CRY protein activation. KL001 binds to CRY through the FAD-binding pocket, which is known to be recognized by FBXL3 and mediate proteasomal degradation ([@B95]). The co-crystal structure of the KL001--CRY2 complex revealed that KL001 competes with FAD and interferes with binding of the FBXL3 C-terminal to CRY, thereby stabilizing CRY proteins ([@B28]; [@B59]). Alternatively, we identified a derivative of 2-ethoxypropanoic acid (designated as KS15) that inhibits CRY-mediated feedback on CLOCK/BMAL1-mediated transcription ([@B12]). KS15 directly binds to CRY C-terminal domains, enhancing E-box-mediated transcription in a CRY-dependent manner, and attenuates the circadian oscillations of *Bmal1* and *Per2* promoter activity ([@B12]; [@B34]). Thus, while KL001 and its derivatives strengthen CRY-mediated feedback, KS15 increases basal promoter activity by inhibiting the repressive actions of CRYs on CLOCK/BMAL1-mediated transcription. CRYs are composed of highly conserved N-terminal photolyase homology regions and variable C-terminal extension domains ([@B8]). The putative coiled-coil (CC) domain is located in the C-terminal tail and is highly conserved between CRY1 and CRY2. Previous studies have suggested that CRY C-terminal tails, including the CC domain, are important for nuclear localization and interactions with other core clock proteins ([@B8]; [@B86]). We found that KS15 binding of CRY C-terminal domains significantly inhibits CRY-BMAL1 interactions, but barely affects CRY-PER associations. Thus, KS15 can be used as a distinct scaffold to develop additional derivatives with improved pharmacokinetics, although further SAR studies are required to determine its mechanism of action ([@B34]).

Circadian Nuclear Receptors as Small Molecule Probe Targets
-----------------------------------------------------------

The circadian nuclear receptors, REV-ERBs and RORs, mediate many physiological processes, including circadian rhythms, development, metabolism, immunity, and even various brain functions. Members of the nuclear receptor superfamily are ligand-activated transcription factors that act as intracellular receptors for cell-permeable ligands. Thus, nuclear receptors are considered as one of the primary molecular classes suitable for drug targets. Interestingly, REV-ERBs contain atypical ligand-binding domains (LBDs) and lack C-terminal transactivation domains, which are used for interactions with transcriptional co-activators. These features provide a structural basis for constitutively repressive action of REV-ERBs upon binding their target genes transcription. Recent studies have identified endogenous ligands for these circadian nuclear receptors, thereby stimulating the development of synthetic ligands with therapeutic applications to circadian rhythm-related diseases ([@B39]).

Although REV-ERBs were initially identified as orphan nuclear receptors, subsequent studies revealed that heme binds to the LBD of REV-ERBs ([@B64]; [@B99]). The discovery of endogenous REV-ERBs ligands led to the identification of chemical scaffolds that can act as synthetic ligands. The first identified synthetic REV-ERB ligand was GSK4112 ([@B54]). Specifically, GSK4112 is a REB-ERB agonist that enhances recruitment of NCoR and HDAC3 to their target promoters and then represses target gene transcription ([@B21]). While GSK4112 did not exhibit favorable pharmacokinetics, it paved the way for the subsequent development of synthetic REV-ERBs ligands. To improve potency, efficacy, and pharmacokinetics, Burris and colleagues developed additional REV-ERB agonists, such as SR9009 and SR9011, that were more suitable for *in vivo* applications. Both compounds demonstrated therapeutic efficacy of small molecule REV-ERB modulators in the treatment of circadian-related metabolic diseases and sleep disorders ([@B77]). Although there are several REV-ERBs agonists, SR8278 is the only antagonist that has been identified thus far. SR8278 inhibits the transcriptional repression activity of both REV-ERBs, thereby enhancing RRE-mediated transcription ([@B38]). So far, SR8278 applications *in vivo* have been limited; however, it provides a convenient tool to temporally inhibit REV-ERB activity in target cells or tissues.

Cholesterol and some of its metabolites were initially shown to act as natural ROR ligands. Recent studies revealed that several oxysterols are high-affinity endogenous ROR modulators. Oxysterol ligands bind directly to the RORα/γ LBD and act as inverse agonists by modulating the interaction of co-regulators. As indicated by their names, RORs are evolutionarily related to retinoic acid receptors. Interestingly, all-*trans* retinoic acids recognize the LBD of RORβ, but not RORα/γ, suggesting subtype specificity. Alternatively, the liver X receptor agonist, T0901317, was the first synthetic ligand and inverse agonist identified for RORα/γ ([@B43]). Subsequently, a series of RORα/γ agonists or inverse agonists were developed as reviewed in more detail elsewhere ([@B39]). In a more recent study, Chen et al. identified that nobiletin, a natural polymethoxylated flavone, enhances circadian molecular rhythm amplitudes by acting on RORs ([@B26]).

Implications in Circadian Rhythm-Related Neuropsychiatric Diseases
==================================================================

Considering the impact of the circadian system on a wide range of biological processes, small-molecule circadian modifiers may be used to optimize internal timing for pharmacological treatment and/or to rescue the desynchrony underlying circadian-related diseases. For example, SR9009/9011 and nobiletin have beneficial effects on high-fat diet-induced metabolic disturbances that affect a wide range of molecular, metabolic, and behavioral rhythms ([@B37]; [@B77]; [@B26]). Dysregulation of circadian rhythmicity is also associated with various neuropsychiatric disorders, including sleep disorders, affective disorders, substance use disorders, schizophrenia, and neurodegeneration ([@B33]). However, determining whether the changes in brain function associated with these disorders manifest because of circadian dysregulation or additional malfunctions is controversial. Compelling evidence suggests that the effects of circadian disruption on brain function are attributable to both the SCN and local oscillators in discrete brain regions. Here, we will discuss how the circadian clock is involved in neuropsychiatric disorders and the potential implications of clock modulators for those diseases.

Sleep Disorders
---------------

Given that the circadian system constitutes one of the two major mechanistic facets of sleep, small molecule clock modulators may be applicable for circadian rhythm-related sleep disorders. Indeed, abnormal sleep phenotypes have been reported in mutant mice with defective alleles of core clock genes as well as genes mediating post-translational modification of clock proteins ([@B72]). For example, familial advanced sleep phase syndrome can be caused by either phosphorylation-defective mutations in human *PER2* or by mutant alleles for protein kinases such as CK1δ ([@B83]; [@B96]). A variation in human *PER3* is also associated with differential sleep homeostasis, particularly after sleep deprivation ([@B89]). Furthermore, REV-ERBs appear to have a certain role in both homeostatic and circadian regulation of sleep. In mutant mice with a defective allele of *Rev-erbα* gene, sleep/wake distributions are advanced in comparison with the environmental light-dark cycle. Moreover, both electroencephalogram delta power and sleep consolidation were also significantly reduced after sleep onset, suggesting a slower increase of homeostatic sleep need during wakefulness in the mutant mice ([@B51]). Interestingly, daytime administration of REV-ERB agonists induced wakefulness and suppressed both slow-wave and rapid eye movement sleep ([@B3]). Thus, pharmacological manipulation of the circadian clock may be used to treat circadian rhythm-related sleep disorders, such as sleep fragmentation, abnormal sleep phase syndromes, and non-24-h sleep-wake rhythm disorders.

Mood-Related Psychiatric Disorders
----------------------------------

Mood spectrum disorders, including major depression, bipolar disorder, seasonal affective disorder, and various addiction-related diseases, are the most attractive targets for clock modulators. Patients with mood disorders commonly suffer from disrupted sleep/wake cycles and dysregulated diurnal mood variations. Furthermore, several genetics studies have reported significant associations of clock genes with the onset and symptoms of affective disorders ([@B94]; [@B52]). Similarly, mutant mice with defective clock genes exhibit behavioral phenotypes linked with abnormal despair, anxiety, and reward responses ([@B53]; [@B24]; [@B13]; [@B70]). The key mediators of circadian mood regulation are central monoamine systems, making them ideal therapeutic targets for affective disorders. These monoamine systems are related to circadian disruption, as mutant mice bearing defective *ClockΔ19* demonstrate mania-like behaviors characterized by hyperactivity, as well as decreased depression- and anxiety-related behaviors. They also demonstrate increased cocaine sensitization with enhanced dopamine (DA) transmission ([@B53]). More recently, our data demonstrating mania-like phenotypes in *Rev-erbα*-deficient mice revealed that REV-ERBα connects the molecular clock with the midbrain DA system ([@B13]). CLOCK and REV-ERBα expression in DA neurons evokes daily variations in DA biosynthesis and transmission in mesocorticolimbic DA circuits, particularly through transcriptional control of tyrosine hydroxylase, a rate-limiting enzyme for catecholamine biosynthesis. Monoamine oxidase-mediated DA clearance in post-synaptic sites is also reported to be under the circadian control of NPAS2 and BMAL1 ([@B24]). Taken together, these findings indicate that the circadian clock tightly controls DA biosynthesis, transmission, and turnover.

Interestingly, acute administration of the REV-ERB antagonist, SR8278, to the ventral midbrain produces mania-like behaviors with increased DA production and release ([@B13]). While both REV-ERB agonists and antagonists reduce anxiety-like behaviors in mice, REV-ERB agonists do not significantly affect despair-based behaviors ([@B3]; [@B13]). This discrepancy may arise from the presence of two REV-ERB isoforms that could interact with synthetic ligands. Although SR8278 promotes mania in wild-type mice, it acts as an anti-depressant in a mouse genetic model of depression ([@B23]). Nobiletin also has anti-depressant-like effects that are comparable with those of fluoxetine. These effects are also prevented by inhibitors for monoamine transmission ([@B98]). These findings strongly suggest that circadian clock modulators have therapeutic potential for mood-related psychiatric disorders, but also warn of potential risks in their clinical applications to circadian rhythm-related sleep and metabolic diseases.

Neurodegenerative Diseases
--------------------------

Circadian disruptions are common among patients with neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), and Huntington's disease, despite the range in pathogenesis and associated symptoms of these diseases ([@B32]). Circadian disturbances manifesting as alterations in sleep-wake cycles, hormone secretion, and diurnal mood regulation precede the cognitive and motor symptoms characteristic of these diseases. Indeed, various forms of AD models have exhibited phenotypes linked with circadian and/or sleep abnormalities ([@B92]; [@B20]; [@B79]; [@B41]), and neurodegenerative lesions in the SCN have been proposed as a possible underlying mechanism ([@B79]; [@B104]). Conversely, amyloid-beta (Aβ) pathologies are affected by the sleep-wake cycle in both mice and humans ([@B35]; [@B62]). The sleep-wake cycle controls a diurnal rhythm found in Aβ levels in brain interstitial fluid (ISF) and sleep deprivation exacerbated Aβ plaque burden in an AD mouse model ([@B35]). These findings collectively suggest mutual interactions between circadian disturbances and neurodegenerative pathologies.

Considerable evidence suggests that circadian disturbances may play more direct roles in the progression of neurodegenerative diseases, particularly in sporadic disease forms ([@B56]; [@B88]). Specifically, genetic variations in clock gene loci are associated with neurodegenerative diseases ([@B22]). Furthermore, the absence of functional BMAL1 is associated with various phenotypes of premature aging, increased oxidative stress, induced age-dependent gliosis, and neurodegeneration in the presence of neurotoxic assaults ([@B40]; [@B57]). Recently, [@B57] demonstrated that loss of central circadian rhythms accelerates amyloid plaque accumulation along with disruption of daily Aβ oscillations in hippocampal ISF, whereas loss of local BMAL1 in extra-SCN brain regions promotes fibrillar plaque deposition and increased APOE expression, suggesting both central and local brain clock influence AD pathogenesis ([@B42]). It was also demonstrated that the expression of several AD risk genes, including *Bace1* and *Bace2*, are under the control of cellular clockworks ([@B50]). In addition to AD, genetic abrogation of REV-ERBα and chronic circadian disruption were shown to exacerbate neurotoxin-induced PD-like phenotypes and neuroinflammation-mediated DA neuron loss ([@B47]; [@B36]). Thus, chronic circadian disruption by either environmental or genetic causes is likely a risk factor for sporadic forms of neurodegenerative diseases, and neuroinflammatory dysregulation could be a link between circadian dysfunction and neurodegeneration ([@B57]; [@B47]).

These findings also suggest that circadian rhythm-based therapeutics may delay the progression and severity of neurodegenerative diseases. Such chronobiological interventions for neuropsychiatric disorders, such as affective disorders and neurodegeneration, include bright-light therapy and timed melatonin administration ([@B17]). Previous studies have suggested that timed light exposure and/or melatonin administration partially improve sleep- and circadian rhythm-related symptoms of AD and PD ([@B1]; [@B68]; [@B87]). However, whether bright light has long-lasting beneficial effects on cognitive or motor-skill impairments in AD or PD patients remains unclear. Alternatively, these impairments may be treated with small-molecule modulators of clock proteins. Indeed, nobiletin attenuated memory impairments and amyloid pathology in transgenic mouse models of AD ([@B61]; [@B58]) and ameliorated motor and cognitive deficits in MPTP-induced PD mice ([@B97]). Considering that clock proteins have been implicated in cellular antioxidant responses ([@B48]; [@B93]), amelioration of oxidative damage may be an additional potential mechanism by which clock modulators delay neurodegeneration.

Possible Mode of Actions: Brain Region-Specific and Systemic Mechanisms
-----------------------------------------------------------------------

Although still in preclinical development, small-molecule modifiers of clock components may exert beneficial effects at multiple levels ([@B80]). The simplest modes of action could involve cellular clock-dependent modulation of transcriptional networks or signaling pathways that are responsible for pathological states due to malfunction. Considering that the cellular clock coordinates diverse cellular pathways, pharmacological manipulation of clock components may have pleiotropic benefits, comparable to combination-therapy approaches. For example, a REV-ERBs antagonist enhanced both DA biosynthesis and activity-dependent neurotransmitter release, which may both contribute to its anti-depressant-like effects ([@B13]; [@B23]). In this context, it should be also noted that some molecular targets of established drugs have been identified to follow oscillatory expression or to be directly controlled by the cellular clock. [@B30] identified sets of oscillatory genes across multiple tissues in mice. Additionally, they found that more than 20% of the 100 best-selling drugs with short half-lives involved circadian gene targets; these drugs included widely used drugs for neuropsychiatric disorders such as insomnia, depressive disorders, and attention-deficit hyperactivity disorders ([@B101]). These findings imply therapeutic potential of clock modulators that can be also considered for combinational therapy with existing treatments to improve their efficacy.

Systemic restoration or stabilization of the circadian system may also mediate therapeutic effects of clock modulators, plausibly by strengthening the autonomous oscillations of the SCN pacemaker and/or by helping the synchronization between brain clocks. As noted earlier, behavioral interventions to restore circadian rhythm and sleep have been reported to ameliorate some symptoms of affective disorders and neurodegeneration ([@B17]; [@B80]). Furthermore, co-morbidities among circadian rhythm-related diseases are frequently found. For example, there is a bi-directional association between metabolic syndromes and mental health disorders including bipolar disorder, major depression, anxiety, attention-deficit hyperactivity disorder, schizophrenia, and autism spectrum disorders ([@B60]). Because circadian rhythms coordinate the multiple brain systems responsible for affective, cognitive, and metabolic functions, dysregulation of circadian clocks has been proposed to play a central role in cardio-metabolic co-morbidity in psychiatric disorders ([@B4]). It can be, therefore suggested that systemic actions of clock-targeting pharmaceuticals may provide additional distinct preventive or therapeutic strategies for co-morbid disorders.

Concluding Remarks
==================

Circadian clocks govern a wide spectrum of biochemical, physiological, and behavioral processes. Disruption or misalignment of the intrinsic rhythms are considered as a risk for the pathogenesis of various chronic diseases. Therefore, improving our understanding of the impact of the circadian system on brain functions may lead to the development of novel treatment schemes, increase efficacious therapeutic delivery, and improve preventative strategies for circadian rhythm-related brain disorders. In this context, development of chemical clock modulators may primarily contribute to revealing the functional relevance of the molecular clock across discrete brain regions because these small molecules can be used to dynamically control location-specific cellular clocks in the brain. More importantly, these molecules could provide lead structures for novel therapeutics for prevention and treatment of neuropsychiatric disorders.
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